Istituto Superiore di Sanità |
|
299 Viale Regina Elena | |
00161 - Roma (I) |
Project leader
|
Project staff
Description of the organisation
The Istituto Superiore di Sanità (ISS) is the leading technical and scientific public body of the Italian National Health Service. Its activities include research, control, training and consultation in the interest of public health protection.
Department of Therapeutic Research and Medicines Evaluation:The mission of the Department is: to contribute to public health by controlling the quality, efficacy and safety of drugs and through research into new drugs and treatments for human diseases.
The research activities of the Department, which are carried out in cooperation with other Departments of the Institute, universities, the Scientific Institutes for Research and Care (IRCCS) and other national and international research centres, cover several aspects of pharmacological research, including the synthesis of new compounds and preclinical studies of their mechanisms of action and the coordination of large-scale national and international multicentre clinical trials. Specific areas of involvement include the use of drugs in paediatric patients, cardiovascular diseases, metabolic and endocrine diseases, aging-related conditions, neurological and neurodegenerative disorders, tumours, viral diseases such as HIV/AIDS, and drug-related conditions such as addiction, drug resistance and practice of doping in sport.
The Department is also actively engaged in innovative sectors of modern drug research, such as molecular pharmacology, pharmacokinetics and pharmacogenetics. The control activities of the Department range from ascertaining the chemical purity and efficacy of proprietary and generic drugs to the evaluation of preclinical safety, the monitoring of phase I trials of new drugs and innovative therapies, the technical and scientific examination of applications for licences at national and European level, the monitoring of new drugs after placement on the market and of drug-related adverse effects, and the dissemination of information to promote the proper use of drugs.
Previous experience
Profile of staff members
Main tasks in the project
News
The fifth ADDUCE Newsletter is now available!
Here, you can read about the finalisation of the project,
the European Medicines Agency and General Assembly meetings
and the dissemination of the results!
Did you participate in the ADDUCE studies and are you curious about the latest news on the project?
Here you can find some information!
News for children, April 2015
News for adolescents, April 2015
News for parents, April 2015
Read more about the ADDUCE studies:
and much more in the ADDUCE Newsletter 3, March 2015
The second ADDUCE Newsletter is available!
Read more about the 2 main ADDUCE studies:
-
WP3: prospective open-label methylphenidate
pharmacovigilance study - WP8: long-term cardiovascular effects of methylphenidate use
and much more in the ADDUCE Newsletter 2, February 2013
Events
16 - 19 OCTOBER 2016:
4rd EUNETHYDIS International Conference on ADHD, Berlin - Germany
from basis neuroscience to optimised clinical care
17 & 18 APRIL 2016:
ADDUCE Consortium meeting, London - UK
28 - 31 MAY 2015:
5th World Congress on ADHD: from Child to Adult Disorder, Glasgow - Scotland
20 & 21 APRIL 2015:
ADDUCE Consortium meeting, Salina - Italy
21 - 24 MAY 2014:
3rd EUNETHYDIS International Conference on ADHD, Istanbul - Turkey
ADHD and related disorders
19 & 20 MAY 2014:
ADDUCE Consortium meeting, Istanbul - Turkey
3 - 6 OCTOBER 2013:
23rd EUNETHYDIS Network Meeting, Prague Czech Republic
A meeting of the European Network of Hyperkinetic Disorders
6 - 9 JUNE 2013:
4th World Congress on ADHD: from Childhood to Adult Disease, Milan - Italy
4 & 5 JUNE 2013:
ADDUCE Consortium meeting, Milan - Italy
6 & 7 JUNE 2012:
ADDUCE Consortium meeting, Cagliari - Italy
23 MAY 2012:
2nd EUNETHYDIS International Conference on ADHD, Barcelona - Spain